Welcome to our dedicated page for Biomea Fusion news (Ticker: BMEA), a resource for investors and traders seeking the latest updates and insights on Biomea Fusion stock.
Biomea Fusion, Inc. (Nasdaq: BMEA) is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for diabetes and obesity, and its news flow reflects this focus on metabolic disease. Company updates frequently center on the progress of its two main investigational programs: icovamenib, an oral covalent menin inhibitor for insulin-deficient diabetes, and BMF-650, a next-generation oral GLP-1 receptor agonist candidate for obesity and related metabolic disorders.
News items for BMEA commonly include clinical trial milestones, such as Phase II data readouts for icovamenib in type 2 diabetes, long-term follow-up results, and the initiation or advancement of studies like COVALENT-111, COVALENT-121, COVALENT-211, COVALENT-212, and GLP-131. Biomea Fusion also reports on preclinical findings, including combination data for icovamenib with GLP-1–based therapies and weight-loss and pharmacology data for BMF-650 in animal models.
Investors following BMEA news will also see corporate and financial announcements, such as quarterly financial results, cost-management updates, and underwritten offerings of common stock and warrants. The company regularly issues press releases about its participation in scientific and investor conferences, including oral presentations at diabetes and obesity meetings and fireside chats at healthcare investment conferences.
This news page aggregates these disclosures so readers can track Biomea Fusion’s clinical progress, scientific presentations, financing activities, and other material events. For those monitoring the development of investigational therapies in diabetes and obesity, the BMEA news feed offers a centralized view of the company’s reported milestones and public communications over time.
Biomea Fusion (Nasdaq: BMEA) reported Q3 2025 results and clinical progress on Nov 4, 2025. Key clinical highlights include durable 52‑week Phase II icovamenib data showing a sustained 1.5% mean HbA1c reduction at Week 52 in severe insulin‑deficient T2D (Arm B, p=0.01) and a 1.3% HbA1c reduction in GLP‑1 treated patients. Icovamenib showed no treatment‑related serious adverse events in the 52‑week follow‑up. The company dosed the first patient in Phase I for BMF‑650 and presented combination preclinical data with semaglutide.
Finance and operations: Biomea raised approximately $68M gross via two public offerings, held $47.0M cash at Sept 30, 2025, reduced operating expenses >50% YoY, and cut headcount to ~40, extending runway into Q1 2027.
Biomea Fusion (Nasdaq:BMEA) will present two poster presentations at ObesityWeek 2025, held November 4-7, 2025 in Atlanta, Georgia.
The posters scheduled for November 4, 2025 at 7:30 p.m. ET cover:
- Poster-085: Preclinical efficacy of BMF-650, an oral small-molecule GLP-1 receptor agonist.
- Poster-136: Icovamenib plus semaglutide: combination data showing enhanced weight loss while preserving lean mass in ZDF rats.
All abstracts will be published in the peer-reviewed Obesity journal supplement and additional information will be provided in line with ObesityWeek abstract embargo policies.
Biomea Fusion (Nasdaq: BMEA) announced the first patient has been dosed in a Phase I trial of BMF-650, an oral small-molecule GLP-1 receptor agonist for obesity. Preclinical primate studies showed dose-dependent weight loss: ~12% at 10 mg/kg and ~15% at 30 mg/kg over 28 days, with appetite suppression and a favorable safety profile. The Phase I study will evaluate safety, tolerability and preliminary efficacy in overweight or obese participants, with 28-day weight-loss data at the highest dose expected in the first half of 2026.
Biomea Fusion (Nasdaq: BMEA) will participate in Citi's SMID Biotech C-Suite Fireside Chat Series on Thursday, October 23, 2025 at 8:00 a.m. PT / 11:00 a.m. ET. A live audio webcast will be available via the company's Investors & Media site and a replay will be posted after the event. The company is a clinical-stage diabetes and obesity firm and will join the session as scheduled.
Investors can access the live audio webcast and subsequent replay at https://investors.biomeafusion.com/news-events/events.
Biomea Fusion (Nasdaq: BMEA) priced an underwritten public offering on Oct 7, 2025 consisting of 11,195,121 shares of common stock with accompanying warrants and up to 1,000,000 pre-funded warrants and accompanying warrants. An underwriter option covers up to 1,829,268 additional shares/warrants. Each share plus warrant is priced at $2.05; each pre-funded warrant plus warrant at $2.0499. Accompanying warrants are immediately exercisable at $2.50 and expire three years from issuance. Gross proceeds to the company are expected to be approximately $25.0 million, before fees and expenses, with closing expected on Oct 8, 2025 subject to customary conditions.
Biomea Fusion (Nasdaq: BMEA) announced on Oct 6, 2025 that it has commenced an underwritten public offering of its common stock and accompanying warrants, with pre-funded warrants offered to certain investors in lieu of common stock. The company said it will grant underwriters a 30-day option to purchase up to an additional 15% of the shares and/or warrants as overallotment. All securities in the proposed offering are to be sold by Biomea and the offering is subject to market and other conditions, with no assurance it will be completed on specific terms or timing.
The offering is being managed by Jefferies and will be made under an effective Form S-3 registration (filed Aug 5, 2025; declared effective Aug 15, 2025); a preliminary prospectus supplement will be filed with the SEC when available.
Biomea Fusion (Nasdaq: BMEA) reported positive 52-week results from its Phase II COVALENT-111 trial of icovamenib in type 2 diabetes, showing durable, post-treatment glycemic benefit and a favorable safety profile.
Key outcomes include a durable HbA1c reduction of 1.2% (p=0.01) in severe insulin-deficient patients through Week 52, a strongest Arm B effect of 1.5% (p=0.01, n=6), and a 1.3% (p=0.05, n=11) reduction at Week 52 in patients on GLP-1 therapy who had not reached targets. No treatment-related serious adverse events or discontinuations were reported. Planned Phase IIb and Phase II starts expected in Q4 2025. A conference call is scheduled for Oct 7, 2025, 8:30 AM ET.
Biomea Fusion (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, has granted stock options to one new employee. The compensation committee approved non-qualified stock options to purchase 48,000 shares of common stock on September 24, 2025.
The stock options will vest quarterly over four years, with 1/16 of the shares vesting each quarter, contingent on continued employment. The grant was made under Biomea's 2023 Inducement Equity Plan, adopted on November 17, 2023, and complies with Nasdaq Listing Rule 5635(c)(4) as an employment inducement grant.
Biomea Fusion (NASDAQ:BMEA) presented promising preclinical data for its menin inhibitor icovamenib in combination with semaglutide at the 61st EASD Annual Meeting. The combination therapy demonstrated significant improvements in a Type 2 Diabetes animal model, including a 60% reduction in fasting blood glucose and 50% lower glucose AUC compared to semaglutide alone.
Key findings showed the combination achieved greater body weight reduction (-12.5% vs -3.4%) while preserving lean mass, and improved beta cell function. Additionally, Biomea announced FDA clearance of their IND for BMF-650, their oral GLP-1 receptor agonist, with Phase I obesity trial data expected in H1 2026.
The company plans to advance clinical evaluation of icovamenib with GLP-1 therapies in a Phase II study starting in H2 2025.Biomea Fusion (Nasdaq: BMEA) reported Q2 2025 financial results and key developments for its diabetes and obesity pipeline. The company presented three significant studies at ADA 2025 highlighting icovamenib's therapeutic potential in type 2 diabetes, showing durable HbA1c reduction and improved beta-cell function. Their next-generation oral GLP-1 receptor agonist, BMF-650, demonstrated up to 15% weight reduction in non-human primates.
The company raised $42.8 million through a public offering, extending cash runway into H2 2026. Q2 2025 resulted in a net loss of $20.7 million, compared to $37.3 million in Q2 2024. Biomea reduced its workforce and expects quarterly operational expenses to be approximately 40% lower than the previous quarter.